Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
about
Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum ComplexesA potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxiaAlbumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerImmunosuppressive, anti-inflammatory and anti-cancer properties of triptolide: A mini reviewIs there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yesEvolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous HistologiesAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsExploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesEnabling anticancer therapeutics by nanoparticle carriers: the delivery of PaclitaxelRecent progress in the development of polysaccharide conjugates of docetaxel and paclitaxelPolymeric micelles for multi-drug delivery in cancerCys34-PEGylated Human Serum Albumin for Drug Binding and DeliveryMicrotubule-binding agents: a dynamic field of cancer therapeutics.Castor Oil: Properties, Uses, and Optimization of Processing Parameters in Commercial ProductionSafety of Nanoparticles in MedicineMicro/nanofabricated platforms for oral drug deliveryKCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacologyCyclooxgenase-2 inhibiting perfluoropoly (ethylene glycol) ether theranostic nanoemulsions-in vitro studyIn vitro susceptibilities of wild and drug resistant leishmania donovani amastigote stages to andrographolide nanoparticle: role of vitamin E derivative TPGS for nanoparticle efficacyThe effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancerEfficient drug delivery of Paclitaxel glycoside: a novel solubility gradient encapsulation into liposomes coupled with immunoliposomes preparationPeritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugsPhase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumorsMicroemulsions for oral administration and their therapeutic applicationsClinical Translation of Nanomedicine.Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery.Smart Polymeric Gels: Redefining the Limits of Biomedical DevicesIntraoperative fluorescence imaging of peripheral and central nerves through a myelin-selective contrast agent.Flash nanoprecipitation: particle structure and stability.Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism.nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenograftsAn open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016).Photodynamic therapy with decacationic [60]fullerene monoadducts: effect of a light absorbing electron-donor antenna and micellar formulation.Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinibPreclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane.Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer.Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.
P2860
Q24289008-4A7D7321-782C-476B-82FE-6AE66A69B971Q24650483-1BC3AA0C-D16F-4AE7-A315-1095CE62700AQ24657308-50A23F4A-1C6A-45A0-9DEE-CEC702B69953Q26746015-BEE17B01-661D-4656-87E6-B6122759EECBQ26766180-6D61CD04-9C2A-4A47-93BC-9A52C3FB6D1BQ26766254-E724527C-23A7-4FBC-B2D5-B0FD86A8BDE1Q26798674-5C920938-5C53-418A-ABF5-0B35509CA9FDQ26828930-2A63F703-5C56-415A-94D7-F32C7394B822Q26999288-D5AA8DBA-F26F-4398-9B7D-12455C73AE51Q27010654-38C554CD-3CA7-4FDA-B97D-94594AFC0629Q27025861-8B744952-57DC-4311-BEE6-662FCE50854BQ27301475-8E6C8115-75CD-4156-9087-1C5267A2A63EQ27690249-A3D2B11D-9D21-45FA-B92B-C8D736799CADQ28066154-6BB498D7-0941-45E3-BE68-0301D5F4A74EQ28083076-797ABDF6-2054-4969-BBF7-15971F0B7E82Q28083448-DB49791E-7843-4F8D-A994-85642073D7D8Q28483753-767EA7AE-B3D9-4C37-964F-871C23E20F96Q28486071-194BD2DA-395F-4E64-9A65-B1D443A39AA3Q28536688-CF551518-5406-4121-B7C8-39A26D477198Q28540889-0A2AA3CB-E2BF-4492-BAE9-D5F279479629Q28543361-84CB4480-40AC-4729-A664-464944B4AD23Q28544821-D231D12B-083D-454C-BBD5-172D19759E7DQ29035867-4792A67B-8099-4E7E-8948-8D99F6880DDBQ29307905-015EA185-C121-4B82-8B56-5F7A5184B96DQ30355939-F5FA7EF8-6E44-4C6D-92D3-D40B7A3FA388Q30465439-1ECBF8DF-BF36-4325-82A4-5DB3748B42D6Q30493829-D9301712-CEBD-4913-9E64-4E1A22E9862CQ30528078-6A256B25-1CF0-4D87-9FD1-1CC0F6B607DDQ30668553-3A7BD320-EDE3-4C33-8D1A-1645BBD29745Q33264052-928EC464-2E38-4D50-96B3-923BF2C28DF0Q33412928-B40E604A-4456-43FD-8564-ADF63E13B6E3Q33427359-F7B94081-858D-4AA6-8676-4C91652FBB17Q33554366-9334F287-5A3E-4324-9F9E-9E98913A7247Q33563915-D0DF2E67-C06E-4916-ADBB-27B3BCEAE03CQ33605398-432D66CC-83DB-4CC3-BC8A-C95FD4A4C626Q33654186-FD3803CE-BB94-413A-A78F-DCBEDC72B827Q33666026-8217E7C5-36F7-4CCE-B820-3776E1964BA7Q33687409-9F67BDCF-FDDB-481B-A113-5B1555BAAB44Q33738990-A862F221-7F2A-4C79-950D-1ED18315F018Q33819310-19F4D107-82AF-40E0-84EB-D68E7E14F518
P2860
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
@ast
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
@en
type
label
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
@ast
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
@en
prefLabel
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
@ast
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
@en
P2093
P1476
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
@en
P2093
Gelderblom H
Sparreboom A
P304
P356
10.1016/S0959-8049(01)00171-X
P577
2001-09-01T00:00:00Z